Front Row Advisors LLC Cardiff Oncology, Inc. Transaction History

Front Row Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 22, 2023	BUY	$1.45 - $2.09 $2 - $4	2 New	2 $0
Q4 2022 Feb 15, 2023	BUY	$1.22 - $1.66 $0 - $0	0 New	0 $0
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $2 - $5	-2 Closed	0 $0
Q2 2021 Aug 23, 2021	BUY	$6.65 - $10.04 $13 - $20	2 New	2 $0
Q1 2021 Apr 28, 2021	SELL	$9.1 - $19.57 $18 - $39	-2 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$0.78 - $5.1 $1 - $10	2 New	2 $0

12.2M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $174M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.